Pelabresib from MorphoSys AG - late-stage blood cancer drug reshapes the pipeline

By Julian Reed, ad hoc news New Launch Desk. Reviewed June 30, 2026, 12:03 PM ET. Details in the imprint.

Pelabresib from MorphoSys AG is the sort of drug name you now hear murmured in quiet hospital corridors, usually over a tablet screen showing bone marrow scans. Oncologists scroll through trial charts, looking for any hint that this BET inhibitor can give myelofibrosis patients a little more time and a little less pain.

What Pelabresib is targeting

Pelabresib is an orally administered small-molecule BET inhibitor in late-stage clinical development for myelofibrosis, a rare but serious blood cancer that scars the bone marrow and impairs its ability to make healthy blood cells. In plain language, the disease gradually turns the soft, spongy center of bones into stiff, fibrotic tissue.

In the United States, myelofibrosis is classified as a myeloproliferative neoplasm and typically affects older adults; patients often face an exhausting mix of anemia, massive spleen enlargement, night sweats, weight loss, and bone pain. Existing therapies such as JAK inhibitors help many people but leave clear gaps, especially around disease modification and anemia.

How Pelabresib is being tested

The centerpiece for Pelabresib right now is the Phase 3 MANIFEST-2 trial, which combines Pelabresib with ruxolitinib, a standard JAK inhibitor, in patients with myelofibrosis who have not previously received JAK inhibitor therapy. MorphoSys reported positive top-line results from this study, describing clinically meaningful spleen volume and symptom improvements.

Before MANIFEST-2, Pelabresib had been evaluated in the Phase 2 MANIFEST trial, including an arm where it was also combined with ruxolitinib in JAK inhibitor-naïve patients and a monotherapy arm in patients with prior JAK inhibitor exposure. Some hematologists at scientific meetings have highlighted reductions in spleen size and symptom burden as early signals that warranted going into Phase 3.

Regulatory status and US angle

Pelabresib is not yet approved in the United States or Europe, so it is not available for routine prescription or pharmacy dispensing. For now, American patients only encounter the compound within clinical trials.

The key U.S. data flow has come at hematology congresses such as the American Society of Hematology (ASH) annual meeting, where updated MANIFEST and MANIFEST-2 results have featured in oral and poster sessions. For U.S. clinicians, these presentations set expectations ahead of potential regulatory filings.

Inside the Pelabresib mechanism

Pelabresib works by inhibiting bromodomain and extra-terminal (BET) proteins, which act as epigenetic readers that regulate gene expression linked to cancer cell survival and inflammatory signaling. The idea is that dialing down these signals can restore a more normal hematopoietic environment in the bone marrow.

In practical terms, patients in trials take Pelabresib as an oral tablet, once daily, in 21-day treatment cycles alongside continuous ruxolitinib dosing. One trial investigator described, in a hallway conversation after a session, how patients appreciated taking “just more pills, not another infusion,” underscoring how route of administration shapes everyday experience.

What the data say so far

According to MorphoSys, the Phase 3 MANIFEST-2 trial met its primary endpoint of spleen volume reduction at week 24 when Pelabresib was added to ruxolitinib, compared with ruxolitinib plus placebo. Secondary endpoints focused on symptom score improvements, reflecting fatigue, night sweats, and bone pain.

Earlier Phase 2 data showed that a proportion of patients achieved at least 35 percent spleen volume reduction and clinically relevant symptom relief when Pelabresib was combined with ruxolitinib. A hematologist quoted in the abstract suggested that the combination might offer deeper and more durable responses than JAK inhibition alone, though full peer-reviewed publications will matter for final judgment.

Safety profile and tolerability

Safety is a central question for any epigenetic therapy. In the MANIFEST trial, the most common treatment-emergent adverse events with Pelabresib included thrombocytopenia, anemia, and gastrointestinal symptoms such as nausea and diarrhea, typically manageable with dose adjustments.

In one ASH poster walk-through, a trial nurse quietly pointed to a bar chart where platelet counts dipped then flattened, explaining that they monitored labs every cycle and had clear rules for dose holds. That sort of operational detail often matters as much to clinicians as the headline efficacy numbers.

Commercial potential and partnerships

Pelabresib has become a key late-stage asset for MorphoSys following the company’s strategic pivot away from some earlier antibody programs. The drug is being co-developed in collaboration with Incyte, which has a strong commercial presence in myeloproliferative neoplasms through ruxolitinib.

Incyte and MorphoSys entered into a global collaboration and licensing agreement for Pelabresib, under which MorphoSys received upfront payments and is eligible for development, regulatory, and commercial milestones, plus royalties on sales if the drug is approved. For U.S. investors, that structure means eventual revenue could come via milestones as well as any future product sales share.

Voices from MorphoSys and clinicians

MorphoSys CEO Jean-Paul Kress has repeatedly highlighted Pelabresib as a cornerstone of the company’s late-stage oncology strategy, describing the MANIFEST-2 data as supporting a potential new standard of care in front-line myelofibrosis if regulators agree.

Outside the company, U.S.-based hematologists interviewed at major congresses have been cautiously optimistic. One clinician in New York described the early Pelabresib data as “promising but still young,” noting that longer-term follow-up on bone marrow fibrosis reversal and overall survival will be critical before changing routine practice.

What it could mean for patients

For patients, the most tangible potential benefit is relief from the crushing fatigue and abdominal discomfort tied to an enlarged spleen, combined with the possibility of delaying disease progression. Trial participants have reported more restful sleep and better appetite when symptoms are controlled, according to investigator summaries.

During one virtual patient advocacy webinar, a participant described adjusting a loose sweater over her ribs and realizing the tender bulge of her spleen felt slightly smaller after months on trial. It is a small, highly personal datapoint, but it helps translate abstract charts into lived experience.

Timeline, access, and pricing questions

MorphoSys has indicated that it aims to progress Pelabresib toward regulatory submissions based on the MANIFEST-2 data package, in collaboration with Incyte. Exact filing dates and potential launch timing remain dependent on ongoing regulatory interactions in the U.S. and Europe.

No list price or reimbursement terms have been set, because Pelabresib is not yet approved. Analysts expect that, if greenlit, pricing would likely be benchmarked against other targeted therapies in myeloproliferative neoplasms, which in the U.S. often carry annual list prices in the low-to-mid six-figure range before discounts.

Context for MorphoSys AG stock

For MorphoSys AG, Pelabresib is one of the most advanced clinical-stage oncology assets and a central topic in earnings calls and investor presentations as the company navigates its transition toward a more focused late-stage pipeline. The commercial fate of this BET inhibitor will heavily influence how investors model MorphoSys AG’s medium-term revenue potential.

Shares of MorphoSys AG (NASDAQ: MOR, ISIN DE0006632003) give U.S. investors exposure to that Pelabresib risk-reward profile through an American depositary receipt listing.

This article was AI-assisted and editorially reviewed. Product information is provided without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Securities trading carries risks up to total loss.

en | DE0006632003 | MORPHOSYS AG | boerse | 69662477 | bgmi